(Q35835156)

10 August 2017

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents (English)

1 reference

10 August 2017

C Le Tourneau

1 reference

10 August 2017

V Servois

1 reference

10 August 2017

V Diéras

1 reference

10 August 2017

L Ollivier

1 reference

10 August 2017

P Tresca

1 reference

10 August 2017

X Paoletti

1 reference

10 August 2017

language of work or name

English

0 references

publication date

26 January 2012

1 reference

British Journal of Cancer

10 August 2017

1 reference

10 August 2017

106

1 reference

10 August 2017

1 reference

10 August 2017

854-857

1 reference

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

Assessing oncologic benefit in clinical trials of immunotherapy agents

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

Sorafenib in advanced hepatocellular carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

The significance of the site of recurrence to subsequent breast cancer survival.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305968

The CT flare response of metastatic bone disease in prostate cancer

24 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.10

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22281665

12 December 2020

inferred from PubMed ID database lookup

Progression-Free Survival Ratio As End Point for Phase II Trials in Advanced Solid Tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22281665

12 December 2020

inferred from PubMed ID database lookup

Tumour growth rates and RECIST criteria in early drug development

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22281665

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/BJC.2012.10

1 reference

Dimensions Publication ID

10 August 2017

1000067411

0 references

Fatcat ID

release_62j5q62bvzgjrcwdgax3cbqahm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/62j5q62bvzgjrcwdgax3cbqahm

24 November 2022

mapped directly with Wikidata item

1 reference

10 August 2017

PubMed publication ID

22281665

1 reference